Dr. Daniel Claassen
Claim this profileVanderbilt University Medical Center
Studies Huntington's Disease
Studies Parkinson's Disease
8 reported clinical trials
9 drugs studied
Area of expertise
1Huntington's Disease
CAG repeat length positive
HTT positive
2Parkinson's Disease
Affiliated Hospitals
Clinical Trials Daniel Claassen is currently running
Neurodevelopment
for Huntington's Disease
Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT). This disease has classically been conceptualized as a neurodegenerative disease. However, recent evidence suggests that abnormal brain development may play an important role in the etiology of HD. Huntingtin (HTT)is expressed during development and through life. In animal studies, the HTT gene has been shown to be vital for brain development. This suggests that a mutant form of HTT (gene-expanded or CAG repeats of 40 and above) would affect normal brain development. In addition, studies in adults who are gene-expanded for HD, but have not yet manifested the illness, (pre-HD subjects) have significant changes in the structure of their brain, even up to 20 years before onset of clinical diagnosis. How far back these changes are evident is unknown. One possibility is that these brain changes are present throughout life, due to changes in brain development,though initially associated with only subtle functional abnormalities. In an effort to better understand the developmental aspects of this brain disease, the current study proposes to evaluate brain structure and function in children, adolescents, and young adults (ages 6-30) who are at risk for developing HD - those who have a parent or grandparent with HD. Brain structure will be evaluating using Magnetic Resonance Imaging (MRI) with quantitative measures of the entire brain, cerebral cortex, as well as white matter integrity via Diffusion Tensor Imaging. Brain function will be assessed by cognitive tests, behavioral assessment, and physical and neurologic evaluation. Subjects that are gene-expanded (GE) will be compared to subjects who are gene non-expanded (GNE). Changes in brain structure and/or function in the GE group compared to the GNE group would lend support to the notion that this disease has an important developmental component.
Recruiting1 award N/A3 criteria
Registry Study
for Huntington's Disease
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.
Recruiting1 award N/A9 criteria
More about Daniel Claassen
Clinical Trial Related3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Daniel Claassen has experience with
- Observational Study
- Meditation
- MRI Methods For Visualizing Hemodynamic And Metabolic Relationships
- AMT-130
- Imitation (sham) Surgery
- Skin Biopsy
Breakdown of trials Daniel Claassen has run
Huntington's Disease
Parkinson's Disease
Neurodegenerative Diseases
Multi-System Atrophy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Claassen specialize in?
Daniel Claassen focuses on Huntington's Disease and Parkinson's Disease. In particular, much of their work with Huntington's Disease has involved CAG repeat length positive patients, or patients who are HTT positive.
Is Daniel Claassen currently recruiting for clinical trials?
Yes, Daniel Claassen is currently recruiting for 2 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Daniel Claassen has studied deeply?
Yes, Daniel Claassen has studied treatments such as Observational Study, Meditation, MRI Methods for Visualizing Hemodynamic and Metabolic Relationships.
What is the best way to schedule an appointment with Daniel Claassen?
Apply for one of the trials that Daniel Claassen is conducting.
What is the office address of Daniel Claassen?
The office of Daniel Claassen is located at: Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States. This is the address for their practice at the Vanderbilt University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.